Valentina Tuninetti, Elisa Virano, Vanda Salutari, Andrea Ricotti, Carmela Pisano, Monika Ducceschi, Giacinto Turitto, Giuseppa Scandurra, Maria Cristina Petrella, Valeria Forestieri, Monica Rizzetto, Serafina Mammoliti, Grazia Artioli, Raffaella Cioffi, Lucia Borsotti, Marco Bellero, Chiara Rognone, Vittoria Carbone, Gabriella Ferrandina, Mara Mantiero, Carmen Azzolina, Eleonora Geninatti, Sandro Pignata, Giorgio Valabrega
BACKGROUND: cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with platinum based chemotherapy based on the results of EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, retrospective cohort, multicenter study aimed at describing clinical outcomes of patients with advanced CC treated with cemiplimab in Italy. METHODS: The primary objective of the study was to assess the feasibility and the replicability of the initial results in a real world setting of cemiplimab nominal use...
March 30, 2024: European Journal of Cancer